Cancer Immunotherapy Market Report: Trends, Forecast and Competitive Analysis to 2030
Cancer Immunotherapy Trends and Forecast
The future of the global cancer immunotherapy market looks promising with opportunities in the hospital, cancer research center, and clinic markets. The global cancer immunotherapy market is expected to reach an estimated $162.4 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are rising incidence of cancer conditions, introduction of biosimilars, and growing demand for mAbs.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Cancer Immunotherapy by Segment
The study includes a forecast for the global cancer immunotherapy by technology type, application, end use, and region.
Cancer Immunotherapy Market by Technology Type [Shipment Analysis by Value from 2018 to 2030]:
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer immunotherapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer immunotherapy companies profiled in this report include-
Lucintel forecasts that lung will remain the largest segment over the forecast period.
Within this market, hospital will remain the largest segment over the forecast period.
North America will remain the largest region over the forecast period.
Features of the Global Cancer Immunotherapy Market
Market Size Estimates: Cancer immunotherapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Cancer immunotherapy market size by technology type, application, end use, and region in terms of value ($B).
Regional Analysis: Cancer immunotherapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different technology types, applications, end uses, and regions for the cancer immunotherapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer immunotherapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the cancer immunotherapy market size?
Answer: The global cancer immunotherapy market is expected to reach an estimated $162.4 billion by 2030.
Q2. What is the growth forecast for cancer immunotherapy market?
Answer: The global cancer immunotherapy market is expected to grow with a CAGR of 10.4% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the cancer immunotherapy market?
Answer: The major drivers for this market are rising incidence of cancer conditions, introduction of biosimilars and growing demand for mAbs.
Q4. What are the major segments for cancer immunotherapy market?
Answer: The future of the cancer immunotherapy market looks promising with opportunities in the hospital, cancer research center, and clinic markets.
Q5. Who are the key cancer immunotherapy market companies?
Answer: Some of the key cancer immunotherapy companies are as follows:
Answer: Lucintel forecasts that lung will remain the largest segment over the forecast period.
Q7. In cancer immunotherapy market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the cancer immunotherapy market by technology type (monoclonal antibodies, cytokines & immunomodulators, and others), application (lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others), end use (hospitals, cancer research centers, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Cancer Immunotherapy Market, Cancer Immunotherapy Market Size, Cancer Immunotherapy Market Growth, Cancer Immunotherapy Market Analysis, Cancer Immunotherapy Market Report, Cancer Immunotherapy Market Share, Cancer Immunotherapy Market Trends, Cancer Immunotherapy Market Forecast, Cancer Immunotherapy Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
The future of the global cancer immunotherapy market looks promising with opportunities in the hospital, cancer research center, and clinic markets. The global cancer immunotherapy market is expected to reach an estimated $162.4 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are rising incidence of cancer conditions, introduction of biosimilars, and growing demand for mAbs.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Cancer Immunotherapy by Segment
The study includes a forecast for the global cancer immunotherapy by technology type, application, end use, and region.
Cancer Immunotherapy Market by Technology Type [Shipment Analysis by Value from 2018 to 2030]:
- Monoclonal Antibodies
- Cytokines & Immunomodulators
- Others
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head & Neck Cancer
- Others
- Hospitals
- Cancer Research Centers
- Clinics
- Others
- North America
- Europe
- Asia Pacific
- The Rest of the World
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer immunotherapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer immunotherapy companies profiled in this report include-
- Novartis
- Merck KGaA
- F. Hoffmann-La Roche
- Bayer
- Bristol-Myers Squibb
- AstraZeneca
- Johnson & Johnson
- Eli Lily
- Amgen
- Pfizer
Lucintel forecasts that lung will remain the largest segment over the forecast period.
Within this market, hospital will remain the largest segment over the forecast period.
North America will remain the largest region over the forecast period.
Features of the Global Cancer Immunotherapy Market
Market Size Estimates: Cancer immunotherapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Cancer immunotherapy market size by technology type, application, end use, and region in terms of value ($B).
Regional Analysis: Cancer immunotherapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different technology types, applications, end uses, and regions for the cancer immunotherapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer immunotherapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the cancer immunotherapy market size?
Answer: The global cancer immunotherapy market is expected to reach an estimated $162.4 billion by 2030.
Q2. What is the growth forecast for cancer immunotherapy market?
Answer: The global cancer immunotherapy market is expected to grow with a CAGR of 10.4% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the cancer immunotherapy market?
Answer: The major drivers for this market are rising incidence of cancer conditions, introduction of biosimilars and growing demand for mAbs.
Q4. What are the major segments for cancer immunotherapy market?
Answer: The future of the cancer immunotherapy market looks promising with opportunities in the hospital, cancer research center, and clinic markets.
Q5. Who are the key cancer immunotherapy market companies?
Answer: Some of the key cancer immunotherapy companies are as follows:
- Novartis
- Merck KGaA
- F. Hoffmann-La Roche
- Bayer
- Bristol-Myers Squibb
- AstraZeneca
- Johnson & Johnson
- Eli Lily
- Amgen
- Pfizer
Answer: Lucintel forecasts that lung will remain the largest segment over the forecast period.
Q7. In cancer immunotherapy market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the cancer immunotherapy market by technology type (monoclonal antibodies, cytokines & immunomodulators, and others), application (lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others), end use (hospitals, cancer research centers, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Cancer Immunotherapy Market, Cancer Immunotherapy Market Size, Cancer Immunotherapy Market Growth, Cancer Immunotherapy Market Analysis, Cancer Immunotherapy Market Report, Cancer Immunotherapy Market Share, Cancer Immunotherapy Market Trends, Cancer Immunotherapy Market Forecast, Cancer Immunotherapy Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
1. EXECUTIVE SUMMARY
2. GLOBAL CANCER IMMUNOTHERAPY MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Cancer Immunotherapy Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Cancer Immunotherapy Market by Technology Type
3.3.1: Monoclonal Antibodies
3.3.2: Cytokines & Immunomodulators
3.3.3: Others
3.4: Global Cancer Immunotherapy Market by Application
3.4.1: Lung Cancer
3.4.2: Breast Cancer
3.4.3: Colorectal Cancer
3.4.4: Melanoma
3.4.5: Prostate Cancer
3.4.6: Head & Neck Cancer
3.4.7: Others
3.5: Global Cancer Immunotherapy Market by End Use
3.5.1: Hospitals
3.5.2: Cancer Research Centers
3.5.3: Clinics
3.5.4: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Cancer Immunotherapy Market by Region
4.2: North American Cancer Immunotherapy Market
4.2.1: North American Cancer Immunotherapy Market by Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others
4.2.2: North American Cancer Immunotherapy Market by End Use: Hospitals, Cancer Research Centers, Clinics, and Others
4.3: European Cancer Immunotherapy Market
4.3.1: European Cancer Immunotherapy Market by Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others
4.3.2: European Cancer Immunotherapy Market by End Use: Hospitals, Cancer Research Centers, Clinics, and Others
4.4: APAC Cancer Immunotherapy Market
4.4.1: APAC Cancer Immunotherapy Market by Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others
4.4.2: APAC Cancer Immunotherapy Market by End Use: Hospitals, Cancer Research Centers, Clinics, and Others
4.5: ROW Cancer Immunotherapy Market
4.5.1: ROW Cancer Immunotherapy Market by Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others
4.5.2: ROW Cancer Immunotherapy Market by End Use: Hospitals, Cancer Research Centers, Clinics, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Cancer Immunotherapy Market by Technology Type
6.1.2: Growth Opportunities for the Global Cancer Immunotherapy Market by Application
6.1.3: Growth Opportunities for the Global Cancer Immunotherapy Market by End Use
6.1.4: Growth Opportunities for the Global Cancer Immunotherapy Market by Region
6.2: Emerging Trends in the Global Cancer Immunotherapy Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Cancer Immunotherapy Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Immunotherapy Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Novartis
7.2: Merck KGaA
7.3: F. Hoffmann-La Roche
7.4: Bayer
7.5: Bristol-Myers Squibb
7.6: AstraZeneca
7.7: Johnson & Johnson
7.8: Eli Lily
7.9: Amgen
7.10: Pfizer
2. GLOBAL CANCER IMMUNOTHERAPY MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Cancer Immunotherapy Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Cancer Immunotherapy Market by Technology Type
3.3.1: Monoclonal Antibodies
3.3.2: Cytokines & Immunomodulators
3.3.3: Others
3.4: Global Cancer Immunotherapy Market by Application
3.4.1: Lung Cancer
3.4.2: Breast Cancer
3.4.3: Colorectal Cancer
3.4.4: Melanoma
3.4.5: Prostate Cancer
3.4.6: Head & Neck Cancer
3.4.7: Others
3.5: Global Cancer Immunotherapy Market by End Use
3.5.1: Hospitals
3.5.2: Cancer Research Centers
3.5.3: Clinics
3.5.4: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Cancer Immunotherapy Market by Region
4.2: North American Cancer Immunotherapy Market
4.2.1: North American Cancer Immunotherapy Market by Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others
4.2.2: North American Cancer Immunotherapy Market by End Use: Hospitals, Cancer Research Centers, Clinics, and Others
4.3: European Cancer Immunotherapy Market
4.3.1: European Cancer Immunotherapy Market by Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others
4.3.2: European Cancer Immunotherapy Market by End Use: Hospitals, Cancer Research Centers, Clinics, and Others
4.4: APAC Cancer Immunotherapy Market
4.4.1: APAC Cancer Immunotherapy Market by Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others
4.4.2: APAC Cancer Immunotherapy Market by End Use: Hospitals, Cancer Research Centers, Clinics, and Others
4.5: ROW Cancer Immunotherapy Market
4.5.1: ROW Cancer Immunotherapy Market by Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others
4.5.2: ROW Cancer Immunotherapy Market by End Use: Hospitals, Cancer Research Centers, Clinics, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Cancer Immunotherapy Market by Technology Type
6.1.2: Growth Opportunities for the Global Cancer Immunotherapy Market by Application
6.1.3: Growth Opportunities for the Global Cancer Immunotherapy Market by End Use
6.1.4: Growth Opportunities for the Global Cancer Immunotherapy Market by Region
6.2: Emerging Trends in the Global Cancer Immunotherapy Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Cancer Immunotherapy Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Immunotherapy Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Novartis
7.2: Merck KGaA
7.3: F. Hoffmann-La Roche
7.4: Bayer
7.5: Bristol-Myers Squibb
7.6: AstraZeneca
7.7: Johnson & Johnson
7.8: Eli Lily
7.9: Amgen
7.10: Pfizer
